Երկիր: Կանադա
Լեզու: անգլերեն
Աղբյուրը: Health Canada
FLUDARABINE PHOSPHATE
MYLAN PHARMACEUTICALS ULC
L01BB05
FLUDARABINE
25MG
SOLUTION
FLUDARABINE PHOSPHATE 25MG
INTRAVENOUS
2ML
Prescription
ANTINEOPLASTIC AGENTS
Active ingredient group (AIG) number: 0123842003; AHFS:
CANCELLED PRE MARKET
2022-02-28
PRODUCT MONOGRAPH Pr FLUDARABINE PHOSPHATE INJECTION Mylan Standard (Fludarabine Phosphate) 25 mg/mL (2 mL per vial) Antineoplastic Mylan Pharmaceuticals ULC 85 Advance Road Etobicoke, ON M8Z 2S6 Date of Preparation: June 24, 2014 Submission Control No: 174683 _ _ _ _ _Page 2 of 51_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ..........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................4 WARNINGS AND PRECAUTIONS ..................................................................................4 ADVERSE REACTIONS ....................................................................................................8 DRUG INTERACTIONS ..................................................................................................10 DOSAGE AND ADMINISTRATION ..............................................................................10 OVERDOSAGE ................................................................................................................11 ACTION AND CLINICAL PHARMACOLOGY ............................................................11 STORAGE AND STABILITY ..........................................................................................13 SPECIAL HANDLING INSTRUCTIONS .......................................................................13 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................14 PART II: SCIENTIFIC INFORMATION ...............................................................................15 PHARMACEUTICAL INFORMATION ..........................................................................15 CLINICAL TRIALS .................................................................................................. Կարդացեք ամբողջական փաստաթուղթը